ARIA
Library/metabolic/Amycretin

Amycretin

Not FDA Approved✓ WADA Permitted
metabolic•clinicalGLP-1/Amylin receptor agonist

First oral GLP-1 receptor agonist developed by Novo Nordisk. Small molecule peptide that can be taken orally rather than injected. Combines GLP-1 receptor agonist activity with amylin receptor agonist effects. Phase 2 demonstrated 13.1% weight loss over 36 weeks with oral dosing.

Confidence
88%
Half-Life ~16 hours
Cost ~$1500/mo
Quick Reference
Routeoral (tablet)
MechanismActivates GLP-1 receptor for appetite suppression and amylin receptor for satiet...
Reviewed2026-06-08

Mechanism of Action

Activates GLP-1 receptor for appetite suppression and amylin receptor for satiety signaling. Oral bioavailability enables non-injectable peptide therapy.

Dosing Protocol

Phase 2: oral tablets titrated from 10mg to 50mg daily over 36 weeks. Phase 3 (OASIS trials) ongoing.

Adverse Effects

Nausea (more manageable than injectable GLP-1s)DiarrheaConstipationHeadacheDecreased appetite

Contraindications

  • Pregnancy
  • History of medullary thyroid carcinoma
  • MEN2
  • Pancreatitis

Storage

Room temperature. Store in original container.